Acute cholecystitis medical therapy

Jump to navigation Jump to search

Acute cholecystitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute cholecystitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines for Management

Case Studies

Case #1

Acute cholecystitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute cholecystitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute cholecystitis medical therapy

CDC on Acute cholecystitis medical therapy

Acute cholecystitis medical therapy in the news

Blogs on Acute cholecystitis medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Acute cholecystitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]

Overview

The mainstay of treatment for acute cholecystitis (calculous and acalculous) is surgery. Pharmacologic medical therapy is recommended for cases of acute cholecystitis in which surgery is delayed. Empiric pharmacologic medical therapies for acute cholecystitis include either amoxicillin-clavulanic acid, cefoxitin, cefotaxime, or ceftriaxone with metronidazole, and ciprofloxacin or levofloxacin with metronidazole. The duration of medical therapy after the cholecystectomy depends on the severity of the disease.

Medical Therapy

  • Pharmacologic medical therapy is recommended for cases of acute cholecystitis (calculous and acalculous) in which surgery is delayed and in complicated cases.[1][2][3][4][5]
  • Antibiotics are not indicated for the conservative management of acute calculous cholecystitis or in patients scheduled for cholecystectomy.[6]

Acute cholecystitis

Add metronidazole to the preferred regimen (1), (2), and (3) if anaerobic bacteria are suspected.

Recommendations of Infectious Diseases Society of America

Infectious Diseases Society of America recommends the following antibiotic regimens for patients with acute cholecystitis:[7]

Acute cholecystitis Drugs recommended
Community-acquired acute cholecystitis of mild-to-moderate severity Cefazolin, cefuroxime, or ceftriaxone
Community-acquired acute cholecystitis of severe physiologic disturbance, advanced age, or immunocompromised state Imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, each in combination with metronidazole^
Acute cholangitis following bilio-enteric anastomosis of any severity Imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, each in combination with metronidazole^
Health care–associated biliary infection of any severity Imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, each in combination with metronidazole, vancomycin added to each regimen^

^ Because of increasing resistance of Escherichia coli to fluoroquinolones, local population susceptibility profiles and, if available, isolate susceptibility should be reviewed.

Adopted from Journal of Hepato-Biliary-Pancreatic Sciences

Duration of therapy

  • The duration of the antibiotic in acute cholecystitis depends on the severity of the disease.[8][9][10]
    • Antibiotic therapy should be discontinued within 24 hours of cholecystectomy for mild cholecystitis unless there is evidence of infection extending outside of the gallbladder.
    • Antibiotic therapy is discontinued within 4-7 days for moderate-severe cholecystitis.
    • In the cases of bacteremia with gram-positive bacteria known to cause infective endocarditis (eg, Enterococcus and Streptococcus), consider continuing antibiotics for 14 days.

References

  1. Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, Hirota M, Miura F, Wada K, Mayumi T, Solomkin JS, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Fan ST, Chen MF, Belli G, Hilvano SC, Kim SW, Ker CG (2007). "Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines". J Hepatobiliary Pancreat Surg. 14 (1): 83–90. doi:10.1007/s00534-006-1160-y. PMC 2784497. PMID 17252301.
  2. "Cholecystitis - ScienceDirect".
  3. Yokoe M, Takada T, Strasberg SM, Solomkin JS, Mayumi T, Gomi H, Pitt HA, Garden OJ, Kiriyama S, Hata J, Gabata T, Yoshida M, Miura F, Okamoto K, Tsuyuguchi T, Itoi T, Yamashita Y, Dervenis C, Chan AC, Lau WY, Supe AN, Belli G, Hilvano SC, Liau KH, Kim MH, Kim SW, Ker CG (2013). "TG13 diagnostic criteria and severity grading of acute cholecystitis (with videos)". J Hepatobiliary Pancreat Sci. 20 (1): 35–46. doi:10.1007/s00534-012-0568-9. PMID 23340953.
  4. Bornscheuer T, Schmiedel S (2014). "Calculated Antibiosis of Acute Cholangitis and Cholecystitis". Viszeralmedizin. 30 (5): 297–302. doi:10.1159/000368335. PMC 4571718. PMID 26535043.
  5. Loozen CS, Oor JE, van Ramshorst B, van Santvoort HC, Boerma D (2017). "Conservative treatment of acute cholecystitis: a systematic review and pooled analysis". Surg Endosc. 31 (2): 504–515. doi:10.1007/s00464-016-5011-x. PMID 27317033.
  6. "Systematic review of antibiotic treatment for acute calculous cholecystitis - van Dijk - 2016 - BJS - Wiley Online Library".
  7. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clin. Infect. Dis. 50 (2): 133–64. doi:10.1086/649554. PMID 20034345.
  8. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Surg Infect (Larchmt). 11 (1): 79–109. doi:10.1089/sur.2009.9930. PMID 20163262.
  9. Hoffmann C, Zak M, Avery L, Brown J (2016). "Treatment Modalities and Antimicrobial Stewardship Initiatives in the Management of Intra-Abdominal Infections". Antibiotics (Basel). 5 (1). doi:10.3390/antibiotics5010011. PMC 4810413. PMID 27025526.
  10. Gomi H, Solomkin JS, Takada T, Strasberg SM, Pitt HA, Yoshida M, Kusachi S, Mayumi T, Miura F, Kiriyama S, Yokoe M, Kimura Y, Higuchi R, Windsor JA, Dervenis C, Liau KH, Kim MH (2013). "TG13 antimicrobial therapy for acute cholangitis and cholecystitis". J Hepatobiliary Pancreat Sci. 20 (1): 60–70. doi:10.1007/s00534-012-0572-0. PMID 23340954.

Template:WH Template:WS